VCYT Stock Analysis
VC
Uncovered
Veracyte Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Veracyte, Inc. is a genomic diagnostics company. The Company offers customized biomarker testing and analytical services. It offers a complete range of in vitro diagnostic (IVD) and companion diagnostic development services to biopharmaceutical companies and diagnostic companies. It offers tests across various diseases, which include Afirma Genomic Sequencing Classifier for thyroid cancer; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer; Prosigna Breast Cancer Assay for breast cancer; Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer; Envisia Genomic Classifier test for interstitial lung diseases; Decipher Bladder Genomic Classifier test for bladder cancer and Immunoscore Colon Cancer Test for colon cancer. It also offers Immunogram, a spatial molecular analysis and bioinformatics tool that integrates genomic, transcriptomic and proteomic data to help researchers understand the intricacies of the tumor immune microenvironment.